Zevra Therapeutics, Inc.
Expected move
InputsNext report
Last report
Largest filed tie
—
13F top-10 QoQ
Top fund weight
Last report1 of 8 at or beyond impliedshaded = implied▲▼ = realized× = |realized| ÷ implied
Zevra Therapeutics, Inc.
10.28
−0.08 · −0.73%
post 10.28 0.00%
+12.82%
vs ±13.4% implied · ×0.96
shaded = implied · ▲▼ = realized
Zevra Therapeutics has 5 disclosed suppliers and 1 disclosed customer in SEC filings.
SentenceUnder our March 2012 termination agreement with Aquestive Therapeutics ("Aquestive"), Aquestive has the right to receive a royalty amount equal to 10% of any value generated by AZSTARYS and any product candidates containing SDX.
ZVRA 10-Kaccession 0001434647-26-000011
SentenceUnder the AZSTARYS License Agreement, Corium is responsible for these regulatory activities going forward, and we cannot guarantee they will be complied with.
ZVRA 10-Kaccession 0001434647-26-000011
SentenceIn May 2022, we purchased all the assets and operations of Orphazyme A/S ("Orphazyme") related to arimoclomol.
ZVRA 10-Kaccession 0001434647-26-000011
SentencePursuant to the Relief License Agreement, Zevra is obligated to pay royalties of 10% of U.S. net sales up to a maximum of $45.0 million, plus specified regulatory milestones, for total payments to Relief of up to $56.5 million.
ZVRA 10-Kaccession 0001434647-26-000011
SentenceUnder the XOMA License Agreement, we paid a $6.0 million regulatory milestone payment earned by XOMA upon the approval of MIPLYFFA on September 20, 2024.
ZVRA 10-Kaccession 0001434647-26-000011
SentenceWe entered into the AZSTARYS License Agreement with Commave pursuant to which we granted an exclusive, worldwide license to Commave to develop, manufacture and commercialize AZSTARYS.
ZVRA 10-Kaccession 0001434647-26-000011
Expected move
Inputs8Q avg ±9.0%·×1.75·rich
straddle ±19.4%
spot 10.28exp Nov 20ATM strike 10ATM straddle 2.35IV 122%